



April 15, 2022

Daniel Fabricant, Ph.D.
Natural Products Association
440 1st Street, NW
Washington, DC 20001

Sent via email to: daniel.fabricant@npanational.org

Dear Petitioner:

Your submission requesting that the Commissioner of Food and Drug to (1) determine that CBD is not excluded from the definition of a dietary supplement under 21 U.S.C. §321(ff)(3)(B); or (2) that the Commissioner exercise enforcement discretion in a specific and selective manner over CBD products following a safety review of a notification on an individual dietary supplement product submitted consistent with 21 C.F.R. Part 190.6. Or, in the alternative, the Agency may recommend and support to the Secretary of HHS, that in his discretion he issue a regulation, after notice and comment, establishing that CBD is lawful under the Act was received and processed under CFR 10.30 by this office on 02/24/2022.

It was assigned docket number FDA-2022-P-0600. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note, the acceptance of the petition for filing is a procedural matter and in no way reflects the Agency's decision on the substantive merits of the petition.

Sincerely,

Dynna Bigby
Supervisory Administrative Proceedings Officer
Dockets Management Staff
FDA/Office of Operations (OO)